Review of NICE Technology Appraisal Guidance No.243; Rituximab for the first-line treatment of stage III-IV follicular lymphoma, and No.226; Rituximab for first line maintenance treatment of follicular non-Hodgkin's lymphoma

Proposal to move the existing guidance to the static list

The planned date for review of the above guidance was May 2014.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

At this time there is no new evidence available that is likely to lead to a change in the existing recommendations. 

There is a clinical guideline for non-Hodgkin’s lymphoma in development, and it is anticipated that the guideline will cross-refer to the two appraisals.  However it may be decided during the development of the guideline that the recommendations should be incorporated into the guideline.

Consequently we propose that both TA243 and TA226 should move to the static list of technology appraisals. 

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

June 2014